Intrexon | XON - Ebit


Intrexon reported $-26.3M in EBIT for its fiscal quarter ending in June of 2024.





Ebit Change Date
Agenus USD -13.31M 19.08M Mar/2025
Alaunos Therapeutics USD -1.19M 148K Sep/2025
Amgen USD 3.96B 464M Dec/2025
Anika Therapeutics USD -4.28M 3.58M Mar/2025
Arrowhead Research USD 40.81M 17.01M Dec/2025
AstraZeneca USD 2.97B 4.48B Dec/2025
Bristol-Myers Squibb USD 3.47B 567M Dec/2025
Gilead Sciences USD 2.96B 551M Dec/2025
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
Heron Therapeutics USD -4.46M 5.76M Sep/2024
Incyte USD 383.88M 47.44M Dec/2025
Intrexon USD -26.3M 2.91M Jun/2024
Karyopharm Therapeutics USD -26.28M 1.84M Sep/2024
Ligand Pharmaceuticals USD 158.89M 115.32M Sep/2025
MacroGenics USD 20.16M 55.51M Sep/2025
MannKind USD -69.24M 28.19M Dec/2025
Merck USD 6.24B 1.32B Dec/2025
Novartis USD -9.19B 13.87B Jun/2025
Rigel Pharmaceuticals USD 447K 1.52M Jun/2024
Roche Holding CHF 9.56B 2.1B Dec/2025
Thermo Fisher Scientific USD 2.3B 226M Dec/2025
Veracyte USD 24.63M 1.52M Dec/2025
Xencor USD -53.63M 6.11M Dec/2025